Files

claude 320cbe4ef2 Deep dive: Pinealon (PEPTIDES.md Section 4.3, Tier 4 — Avoid) — replaces previously lumped mention within Khavinson section with full ~219-line analysis. Discovery: Khavinson group St Petersburg, Glu-Asp-Arg tripeptide as cytogen subset. Proposed Khavinson mechanism (site-directed DNA binding to promoter regions, cell-penetration, transcription factor mimicry, organ-specific gene regulation). Information-theoretic objection as central critique: 3-mer = ~13 bits sequence info vs ~31.5 bits needed for unique site in 3 Gb genome — gap is intrinsic. Three additional convergent biophysics objections: serum peptidase kinetics, absent CPP structural motifs, no ITC/SPR confirmation. Animal evidence covered (Khavinson rodent studies on cognition/ischemia/aging). Human evidence gap (only small unblinded Russian trials). Twitter/social media promotion concern noted honestly. Sourcing concerns (Russian vendors, unverifiable purity). Safety profile (limited Khavinson tox only). Genotype interactions (APOE ε4, DIO2 het, CLOCK CC). Evidence summary table 8 claims. 14 references. Framework alignment: Tier 4 on mechanism implausibility AS CLAIMED + evidence quality grounds. Not claiming biologically inert — door left open for downstream effect via free amino acids or NO-substrate Arg. §4.2 Khavinson reframed as broader methodological critique. GLP-1 cross-ref bumped 4.3 → 4.4. File 734 → 963 lines.

2026-05-24 11:29:47 +08:00

101 KiB

Raw Blame History

PEPTIDES.md — Therapeutic Peptides Through the Bioenergetic Longevity Lens

Sibling document to SUPPLEMENTS.md. Same tier philosophy, same framework lens (pro-mitochondrial, pro-thyroid, pro-glucose-oxidation, anti-PUFA, anti-mTOR-inhibition, pro-anabolic-capacity), but scoped to peptide pharmacology — a class of compounds that has exploded in popular longevity culture in the last decade but suffers from a stark mismatch between marketing claims, animal data, and rigorous human RCT evidence.

Important framing note before reading: Most peptides in this document have one or two orders of magnitude less rigorous human evidence than the supplements covered in SUPPLEMENTS.md. The Sikiric group's three decades of BPC-157 work in rodents is impressive, but the human RCT base for BPC-157 is essentially zero. The Khavinson school bioregulator literature is poorly replicated outside Russian institutions. Mitochondrial peptides (MOTS-c, Humanin, SS-31) have promising mechanistic stories but small human trials. Tier classification in this document reflects framework mechanistic alignment plus evidence quality plus safety margin — not popularity in the longevity peptide subculture.

Sourcing reality check: With the exception of FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, sermorelin in some jurisdictions, PT-141), every peptide in this document is sold through the "research chemical" grey market. Purity, identity, endotoxin load, and contaminant burden vary enormously between suppliers. Self-experimentation with unverified material from unregulated suppliers carries risks separate from the pharmacology of the peptide itself. This is repeatedly flagged throughout.

Framework Introduction

The bioenergetic framework applied to peptide pharmacology
Why peptides as a class — and why caution
Routes of administration and bioavailability primer
The "research chemical" sourcing problem
Cancer concerns for growth-promoting peptides

Tier 1 — Strongly Aligned (direct mitochondrial / regenerative mechanisms with reasonable evidence)

1.1 MOTS-c
1.2 SS-31 (Elamipretide)
1.3 Humanin
1.4 Thymosin α-1 (Zadaxin)

Tier 2 — Aligned, Context-Dependent (specific clinical use cases with framework consistency)

2.1 BPC-157 (Body Protection Compound)
2.2 TB-500 / Thymosin β-4
2.3 GHK-Cu (Copper Tripeptide)
2.4 Pentadeca-Arginate (PDA)
2.5 LL-37 / Cathelicidin
2.6 Selank
2.7 Semax
2.8 DSIP (Delta Sleep-Inducing Peptide)
2.9 Thymalin

Tier 3 — Mixed / Complicated (real effects but framework concerns)

3.1 Tesamorelin (FDA-approved GHRH analogue)
3.2 Sermorelin
3.3 CJC-1295 (with and without DAC)
3.4 Ipamorelin
3.5 Hexarelin
3.6 MK-677 / Ibutamoren (oral GHS — not a peptide; included with note)
3.7 Cerebrolysin
3.8 PT-141 / Bremelanotide
3.9 Kisspeptin-10
3.10 Melanotan I (Afamelanotide / Scenesse)

Tier 4 — Avoid (framework-misaligned or poorly evidenced)

4.1 Melanotan II
4.2 Khavinson School Bioregulators — Methodological Overview (Epitalon, Vesugen, and the wider "peptide bioregulator" pharmacopoeia)
4.3 Pinealon (Glu-Asp-Arg / EDR)
4.4 Semaglutide / Tirzepatide → cross-reference SUPPLEMENTS.md Section 4.7

Framework Introduction

The bioenergetic framework applied to peptide pharmacology

The framework that governs SUPPLEMENTS.md, DIET.md, METABOLISM_AND_AGING.md, and the broader project rests on five pillars:

Pro-glucose-oxidation — glucose oxidation produces the lowest FADH2:NADH ratio at the electron transport chain (ETC), minimising reverse electron transport (RET) at Complex I and the associated ROS burst; respiratory quotient (RQ) 1.0 is the metabolic state with the smallest oxidative damage footprint per ATP synthesised.
Pro-thyroid — T3, basal metabolic rate, body temperature; thyroid axis suppression is mechanistically aligned with most accelerated-aging phenotypes.
Pro-mitochondrial — Complex I-V activity, mitochondrial biogenesis (PGC-1α), membrane potential, fusion/fission balance, mitophagy of damaged units (not blanket mitophagy).
Anti-PUFA — particularly cardiolipin linoleic acid (LA) replacement, which destabilises Complex IV and predisposes to peroxidation chain reactions (4-HNE, MDA, isoprostanes).
Anabolic capacity — lean mass preservation; the framework rejects caloric restriction as a chronic strategy and views muscle as both a metabolic sink and a longevity organ.

Peptides interface with this framework in three distinct ways:

Direct framework matches: mitochondrial peptides (MOTS-c, SS-31, Humanin) and regenerative peptides (BPC-157, TB-500, GHK-Cu, PDA) are mechanistically aligned with pillars 3 and 5.
Framework tensions: growth hormone secretagogues (CJC-1295, ipamorelin, MK-677, hexarelin) elevate IGF-1 and activate mTOR. Mainstream longevity culture treats this as anabolic-positive while simultaneously taking rapamycin to block mTOR — an internally incoherent stack. The bioenergetic framework's view is that mTOR activation in muscle during anabolic windows is desirable (Pillar 5), but chronic elevation of systemic IGF-1 has been associated with cancer incidence in epidemiology (Pollak 2008 Nat Rev Cancer) and is mechanistically pro-growth in a way that does not differentiate healthy from neoplastic tissue.
Framework irrelevance: sexual function peptides (PT-141, kisspeptin) and tanning peptides (melanotan I/II) are largely orthogonal to the framework; they get evaluated on their own pharmacology and safety merits rather than slotted into the bioenergetic schema.

Why peptides as a class — and why caution

Peptides are short polymers of amino acids (typically 2-50 residues — beyond ~50 residues we usually call it a "protein"). Compared with small-molecule drugs they have:

High target specificity — binding via large hydrogen-bond and electrostatic surfaces rather than small hydrophobic pockets; off-target binding is generally rarer.
Endogenous-like signalling — many therapeutic peptides are modified versions of native human signalling peptides (BPC-157 from gastric BPC protein, MOTS-c from mitochondrial 12S rRNA, GHK from a fragment of human α2-macroglobulin / decorin / SPARC).
Short half-lives — most peptides are degraded by serum and tissue proteases within minutes to hours; this is both a safety advantage (clearance is fast) and a practical inconvenience (multiple daily injections, or chemical modification like DAC tags to extend half-life).
Poor oral bioavailability — peptide bonds are hydrolysed by pepsin in the stomach and brush-border peptidases in the intestine; <1% systemic bioavailability is typical for unmodified peptides taken orally. BPC-157 is the controversial exception (Sikiric group claims oral activity; Western pharmacologists are sceptical).

The cautions:

Human RCT evidence is sparse. Most peptide longevity claims rest on rodent data (often from a single lab — Sikiric for BPC-157, Cohen for MOTS-c, Khavinson for the bioregulator series), case reports, or self-experimentation forums. This is a much weaker evidence base than what underpins the Tier 1 supplements in SUPPLEMENTS.md (CoQ10's Q-SYMBIO trial, K2's Rotterdam study, B-complex's VITACOG, taurine's Singh 2023 Science paper).
Cancer concerns for any peptide that promotes angiogenesis, growth, or anti-apoptosis are real but under-investigated. BPC-157 upregulates VEGF. CJC-1295/ipamorelin elevate IGF-1. TB-500 promotes cellular migration including potentially of metastatic cells. None of these has been adequately studied in cancer-bearing humans.
Sourcing is grey-market. See §sourcing problem below.

Routes of administration and bioavailability primer

Route	Typical bioavailability	Notes
Subcutaneous (SC) injection	60-95%	Standard route for most therapeutic peptides; insulin syringes 27-31G
Intramuscular (IM) injection	70-95%	Slightly faster absorption than SC; rarely needed for peptides
Intravenous (IV) injection	100% by definition	Required for some peptides (e.g., SS-31 in trials); home-use rare
Intranasal	1-30% depending on formulation	Effective for some neuropeptides (Selank, Semax, DSIP); olfactory-to-brain route bypasses BBB for small peptides
Oral	<1% for most; controversial for BPC-157	Pepsin and brush-border peptidases destroy peptide bonds; only a handful of peptides survive
Sublingual / buccal	1-10%	Bypasses first-pass metabolism but bioavailability still poor
Transdermal	<1% for most	Skin barrier limits >500 Da molecules; GHK-Cu is a notable exception (small, lipophilic-friendly)

The "research chemical" sourcing problem

Almost every peptide in this document is sold by "research chemical" suppliers with disclaimers stating "not for human consumption." This is a legal fiction allowing trade in compounds not approved for therapeutic use.

Real-world consequences:

Identity verification. Some suppliers send the wrong peptide, or a closely-related cheaper peptide. Mass spectrometry by independent labs (e.g., Janoshik Analytical) has documented identity failures across all major peptide categories.
Purity. HPLC purity ranges from claimed 99% to actual 50-70% in some batches; the remainder is truncated synthesis products, racemised residues (D-amino acids replacing L-), and synthesis solvents.
Endotoxin contamination. Lipopolysaccharide (LPS) from bacterial contamination during synthesis or lyophilisation; injecting LPS-contaminated peptide causes systemic inflammation and can mask or mimic the peptide's true effects.
Bacteriostatic water quality. The diluent used to reconstitute lyophilised peptide should be benzyl alcohol-preserved sterile water; non-sterile diluent introduces bacterial contamination.
No regulatory oversight. No GMP. No batch testing. No adverse event reporting.

Mitigations (partial): order from suppliers who post third-party HPLC and mass spectrometry COAs for each batch, prefer suppliers who use Janoshik or similar independent testing, never inject peptide reconstituted in tap water or unsterile saline.

Cancer concerns for growth-promoting peptides

A unifying concern across BPC-157, TB-500, all GH secretagogues, MK-677, IGF-1 mimetics, and to a lesser extent GHK-Cu:

VEGF and angiogenesis. BPC-157's wound-healing mechanism includes VEGF upregulation. VEGF is the central driver of tumour angiogenesis; bevacizumab (anti-VEGF antibody) is an established cancer therapeutic precisely because blocking VEGF starves tumours. A peptide that promotes VEGF should be presumed to promote tumour angiogenesis in the presence of occult or established malignancy. No human cancer trials exist.
IGF-1 elevation. Sustained IGF-1 elevation is epidemiologically associated with prostate, breast, colorectal cancer incidence (Pollak 2008 Nat Rev Cancer). GH secretagogues (CJC-1295, ipamorelin, hexarelin, MK-677, sermorelin, tesamorelin) all elevate IGF-1. Laron dwarfism (GH-receptor deficient) shows extraordinarily low cancer incidence (Guevara-Aguirre 2011 Sci Transl Med) — the inverse natural experiment.
mTOR activation in dysplastic tissue. Any anabolic signal that activates mTOR in early-stage transformed cells can theoretically accelerate progression. The framework's position is that mTOR activation in muscle during a deliberate anabolic window (after resistance training, post-meal) is desirable; chronic systemic mTOR drive via injected peptides is harder to compartmentalise.

The honest framing: peptides that promote tissue repair, angiogenesis, and anabolism are likely to be net-positive in healthy individuals with no occult malignancy, and likely to be net-negative in individuals with occult or established cancer. Since occult cancer prevalence rises sharply with age (autopsy series show occult prostate cancer in ~30% of men in their 50s, ~50% in their 70s — Sakr 1993), this concern compounds with age.

Tier 1 — Strongly Aligned

1.1 MOTS-c

Tier: 1 — Strongly Aligned Class: Mitochondrial-derived peptide (MDP) Source: Encoded in the mitochondrial 12S rRNA gene (MT-RNR1); 16 amino acids; first characterised by Lee/Cohen lab, USC, 2015 (Cell Metab)

Mechanism summary: AMPK activator; promotes glucose uptake into skeletal muscle independent of insulin via translocation of GLUT4; metabolic stress response peptide that increases in circulation after exercise. Mechanistic match for the framework's pro-glucose-oxidation pillar and Pillar 5 (anabolic capacity preservation via insulin sensitivity).

Framework alignment: Strong — endogenous mitochondrial peptide; AMPK activation via energy stress sensing (NOT supraphysiological Complex I inhibition like metformin); promotes muscle glucose oxidation; no known mTOR drive.

Detailed analysis: pending.

1.2 SS-31 (Elamipretide)

Tier: 1 — Strongly Aligned Class: Cardiolipin-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) Origin: Szeto-Schiller lab, Cornell, 2004; clinical development by Stealth BioTherapeutics

Mechanism summary: Binds selectively to cardiolipin on the inner mitochondrial membrane; stabilises Complex I-IV supercomplex assembly; reduces electron leak and ROS generation; preserves cristae architecture. Tested in clinical trials for Barth syndrome (cardiolipin remodelling defect), primary mitochondrial myopathy, dry AMD, Friedreich's ataxia.

Framework alignment: Strong — direct mitochondrial inner-membrane protection; reduces RET-ROS at Complex I; protects cardiolipin (the framework's central concern given LA-loading from dietary PUFA — see SUPPLEMENTS.md Section 3.4); no growth-pathway activation.

Caveats: Most Phase 3 trials have produced equivocal or negative results on hard clinical endpoints despite positive mechanistic biomarkers (e.g., the MMPOWER-3 trial for primary mitochondrial myopathy missed primary endpoint). The gap between mechanistic elegance and clinical benefit is the central unresolved question.

Detailed analysis: pending.

1.3 Humanin

Tier: 1 — Strongly Aligned Class: Mitochondrial-derived peptide (MDP); 24 amino acids Source: Encoded in mitochondrial 16S rRNA gene (MT-RNR2); discovered by Nishimoto lab 2001 (originally cloned from AD-resistant brain regions, PNAS)

Mechanism summary: Cytoprotective peptide; binds Bax to inhibit apoptosis; activates STAT3; reduces Aβ-induced neurotoxicity; circulating levels decline with age. Centenarian offspring have higher circulating humanin levels than controls (Muzumdar 2009).

Framework alignment: Strong — endogenous mitochondrial peptide; anti-apoptotic specifically in the context of Bax-mediated mitochondrial permeabilisation (preserves functional mitochondria rather than promoting growth); neuroprotective against Aβ (relevant for APOE ε3/ε4 carriers).

Caveats: No commercial human-grade preparation; very limited clinical evidence; analogues (HNG, S14G-humanin) are exclusively research tools.

Detailed analysis: pending.

1.4 Thymosin α-1

Tier: 1 — Strongly Aligned Class: Immune-modulating peptide; 28 amino acids Brand: Zadaxin (FDA orphan drug for chronic hepatitis B/C; approved in 35+ countries outside US)

Mechanism summary: Promotes T-cell maturation from CD4+CD8+ thymocytes; upregulates Th1 cytokines (IFN-γ, IL-2); restores immune competence in immunosenescent or immunosuppressed states; clinically used adjunctively for chronic hepatitis, sepsis (Wu 2013 Crit Care — sepsis mortality reduction), and as cancer immunotherapy adjunct.

Framework alignment: Strong — directly addresses immunosenescence (one of the 12 hallmarks of aging); restores T-cell repertoire diversity; mechanistically distinct from the growth/anabolic peptides and therefore avoids the IGF-1/cancer concerns.

Caveats: Strongest evidence is in immunocompromised contexts (chronic viral hepatitis, sepsis, cancer patients on chemotherapy). Healthy-aging benefit is extrapolated. SC injection, typically 1.6 mg twice weekly.

Detailed analysis: pending.

Tier 2 — Aligned, Context-Dependent

2.1 BPC-157 (Body Protection Compound)

Tier 2 placement rationale: BPC-157 is mechanistically a strong framework match for tissue regeneration (Pillar 5) and the rodent evidence base is unusually deep for a single peptide (30+ years of work from the Sikiric group at the University of Zagreb). It is placed in Tier 2 rather than Tier 1 because (a) human RCT evidence is essentially zero, (b) the VEGF/angiogenesis mechanism creates a theoretical but real cancer concern that has not been adequately studied, and (c) the oral bioavailability claim that underpins much of the practical use case is contested by mainstream pharmacology. A peptide cannot be Tier 1 — Strongly Aligned in this document if its central practical application rests on disputed pharmacokinetics.

Discovery and structure

BPC-157 ("Body Protection Compound 157") is a synthetic pentadecapeptide with the sequence:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
 G   E   P   P   P   G   K   P   A   D   D   A   G   L   V

It is a partial sequence (residues 14a-15a of an unidentified region) derived from a putative human protein originally extracted from gastric juice — "BPC" — by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The parent BPC protein has never been formally characterised at the genomic level (no UniProt entry, no gene name), which has been a recurring criticism of the field: the entire BPC-157 literature rests on a synthetic 15-mer whose claimed natural source remains nebulous. What is uncontroversial is that the synthetic peptide as administered has reproducible biological effects in rodent models.

Molecular weight 1419.5 Da. Stable in gastric juice (Sikiric group claim — see pharmacology discussion below). Soluble in water and saline.

Pharmacology — the oral vs subcutaneous controversy

The pharmacokinetic question central to BPC-157 is whether it is orally bioavailable. The Sikiric group has repeatedly published claims that BPC-157 is stable in gastric juice (its source environment) and active when administered per os or per drinking-water in rodents. Mainstream peptide pharmacology pushes back: peptide bonds are substrates for pepsin in the stomach (cleaves at hydrophobic residues — L14, V15 of BPC-157 are vulnerable), brush-border peptidases in the duodenum, and aminopeptidases in enterocytes. The Pro-Pro-Pro stretch (residues 3-5) confers some pepsin resistance because pepsin disfavours cleavage adjacent to proline, but the C-terminal Leu-Val is a standard pepsin substrate.

To date there is no published pharmacokinetic study in humans showing oral BPC-157 reaches the systemic circulation at meaningful concentrations. Rodent studies showing oral activity are most parsimoniously explained by local gut-epithelial effects (which would still be clinically useful for inflammatory bowel disease and gastric ulcer), rather than systemic activity.

Practical implication:

Local gut effects (IBD, NSAID-induced gastritis, possibly esophageal ulcer): oral dosing plausible.
Systemic effects (tendon healing, brain injury, fracture): subcutaneous injection is the route with the strongest rodent evidence base, and the most defensible from first-principles pharmacology.

Subcutaneous BPC-157: bioavailability presumably ~70-90% based on analogous small peptides; half-life is short (estimated minutes to hours; no rigorous human PK data); local site-of-injection effects may matter (e.g., injecting near a tendon injury may produce higher local concentration).

Proposed mechanisms

Multiple, partially overlapping, none individually proven in humans:

NO / eNOS pathway upregulation. Sikiric group has published extensively on BPC-157 modulating the NO system — reversing L-NAME-induced hypertension, normalising NO-related cardiovascular pathology. Mechanistically this would explain effects on vascular healing and blood flow to injured tissue.
VEGF upregulation. Several Sikiric papers report increased VEGF expression in healing tissues with BPC-157 (Tkalcevic 2007 Eur J Pharmacol, Hsieh 2017 Vascul Pharmacol). VEGF drives angiogenesis — capillary sprouting into wound beds. This is mechanistically the most plausible single explanation for tendon, ligament, and gut healing effects. It is also the basis of the cancer concern (see below).
Growth hormone receptor upregulation in tendon fibroblasts. Chang et al. 2014 (J Appl Physiol) reported that BPC-157 upregulates GH receptor expression on cultured tendon fibroblasts and increases their migratory and proliferative response to GH. This is a partial mechanism explaining the synergy with the GH/IGF-1 axis that the longevity peptide subculture has built protocols around.
FAK-paxillin pathway → fibroblast migration. BPC-157 accelerates the focal adhesion kinase / paxillin signalling that governs cytoskeletal remodelling and cell migration in fibroblasts (Chang 2011 J Appl Physiol). This is mechanistically how a wound contracts and re-epithelialises.
Brain-gut axis / dopaminergic and serotonergic modulation. A surprising body of rodent work shows BPC-157 effects on neuropsychiatric models — antagonism of haloperidol-induced catalepsy (suggesting dopaminergic modulation), antidepressant-like effects in forced-swim test, anxiolytic effects (Sikiric 2017 Curr Pharm Des review). The mechanism is not well-characterised — possibly indirect via gut-brain vagal signalling, possibly direct CNS effects after BBB penetration (unclear if intact peptide crosses).
Reversal of NSAID-induced gut and systemic damage. This is the area with the most consistent rodent data — BPC-157 protects against diclofenac, ibuprofen, indomethacin damage at multiple organ sites (gut, liver, brain).

BPC-157 proposed mechanism network (rodent data; human extrapolation uncertain)
─────────────────────────────────────────────────────────────────────────────────
                                                                             
                  ┌──────────────────────────────────────┐                   
                  │            BPC-157 (SC/PO)           │                   
                  └──┬───────────┬───────────┬───────────┬┘                  
                     │           │           │           │                   
              eNOS/NO↑      VEGF↑       FAK/paxillin   GH-R↑                 
                     │           │           │           │                   
                     ▼           ▼           ▼           ▼                   
              vasorelaxation angiogenesis  fibroblast  GH-responsive         
              endothelial    capillary    migration    tendon/ligament       
              repair         sprouting    cytoskeletal repair                
                     │           │           │           │                   
                     └───────────┴─────┬─────┴───────────┘                   
                                       ▼                                     
                          wound healing / tendon repair                      
                          gut mucosal regeneration                           
                          fracture healing                                   
                                                                             
                  parallel: dopaminergic / 5-HT modulation                   
                          → CNS effects (mood, motor)

Rodent evidence base — the Sikiric corpus

The Sikiric group has published >150 papers on BPC-157 over three decades. The breadth of indications is unusual and, depending on perspective, either remarkable or suspicious:

Tendon healing — Achilles tendon transection model (Krivic 2008 J Orthop Res); accelerated reattachment, increased tensile strength.
Ligament healing — medial collateral ligament transection (Cerovecki 2010 J Orthop Res).
Muscle injury — gastrocnemius crush, denervation atrophy (Novinscak 2008 Med Sci Monit); accelerated functional recovery.
Skin wound — full-thickness incision, burn, deep wound models; accelerated closure.
Bone fracture — segmental defect of rabbit mandible (Sebecic 1999 Bone); accelerated callus formation.
Inflammatory bowel disease — multiple ulcerative colitis models (TNBS, DSS); accelerated mucosal healing, reduced inflammation (Veljaca 1995 J Pharmacol Exp Ther — early work).
Gastric ulcer — stress ulcer, ethanol-induced, NSAID-induced models; cytoprotection appears to be the original framing that gave the peptide its name.
Hepatic protection — paracetamol, CCl4, restraint-stress liver injury models.
Traumatic brain injury — closed-head injury models; reduced lesion volume, improved neurological score (Vukojevic 2018 Neural Regen Res).
Spinal cord injury — improved motor recovery in rat hemisection (Perovic 2019 Med Hypotheses).
Cardiovascular — reversal of L-NAME-induced hypertension; protection in arrhythmia models; reduction of QT prolongation by neuroleptics.
Diabetes-related ulcer healing — accelerated wound closure in alloxan-diabetic rats.

The Sikiric group operates with a consistent experimental design language across these papers — typically rat models, BPC-157 administered IP, IM, SC, or per drinking water at doses ranging 10 ng/kg to 10 µg/kg, with controls of saline ± Pliva (a Croatian pharmaceutical). The consistency of methodology is a strength for internal reproducibility within the lab; the corresponding weakness is that almost all positive BPC-157 evidence comes from a single research group, which violates a basic epistemic principle of multi-lab confirmation.

Independent replication outside Sikiric group: thin but non-zero. Chang group (Taiwan) has published independently on tendon fibroblast effects (2011, 2014). Huang group (China) on diabetic wound healing. Most independent work has been published in lower-impact journals; major Western academic centres have not taken up the peptide in a sustained way.

Human evidence — the critical gap

There are essentially no rigorous human RCTs on BPC-157. A 2019 search of ClinicalTrials.gov returned no registered trials. The "evidence" base for human use consists of:

A small number of case reports (typically self-published or on peptide subculture forums).
Self-experimentation reports on Reddit, peptide forums, and longevity podcasts.
Anecdotal reports from sports medicine practitioners using BPC-157 off-label.

The Sikiric group itself has published exactly one human safety study (Sikiric 1993 Acta Pharmacol Toxicol Hung) on the parent BPC protein (not BPC-157 the peptide), reporting safety at oral doses up to 10 mg in 70 patients — this is an early-1990s safety dossier, not an efficacy trial, and does not transfer to the 15-mer peptide.

This is the single most important fact about BPC-157. The supplement is recommended by some practitioners and used by many self-experimenters on the basis of a rodent literature that — even if every paper is taken at face value — is rodent literature. The translational success rate from positive rodent musculoskeletal-healing data to positive human RCT data is well below 50%.

The cancer concern

BPC-157 upregulates VEGF and promotes angiogenesis. This is the central mechanism of its wound-healing efficacy. It is also a mechanism that, in the presence of occult or established malignancy, would be expected to promote tumour angiogenesis and progression.

The empirical question: has BPC-157 been tested in tumour-bearing rodents? Surprisingly little. A 2019 Sikiric-group paper (Lojo 2016 Inflammopharmacology) reported BPC-157 did not promote VX2 carcinoma growth in rabbits — but this is one paper, in one tumour model, from the originating lab, and the negative finding is the harder result to interpret (could reflect insensitivity of the model rather than absence of effect).

Published human cancer signal: none, because there are no human studies of any size.

Practical framework position:

Healthy adults using BPC-157 for acute tendon/ligament injury at standard doses for limited durations (4-8 weeks) are probably at low cancer-promotion risk in absolute terms.
Chronic continuous use (months to years) in older adults with rising age-associated occult tumour prevalence is harder to defend.
Use in individuals with active malignancy or recent malignancy is strongly contraindicated on first principles.
Use in individuals with strong family history of hormonally-driven cancer (prostate, breast) deserves extra caution.

Safety profile

In rodent studies and case-report human use, BPC-157 has a clean acute safety profile — no serious adverse events reported even at very high doses (10 mg/kg in some rat studies, vs typical human dose ~5 µg/kg = a >1000-fold safety margin).

The unknowns:

Long-term carcinogenicity (no studies).
Long-term immunogenicity (anti-BPC-157 antibodies could develop with chronic SC injection; not studied).
Cardiovascular effects of chronic VEGF and NO modulation (theoretical concern with angiogenesis-promoting agents — could destabilise atherosclerotic plaque vascularisation).
Effects on diabetic retinopathy or wet AMD (any VEGF promoter should be presumed contraindicated in these conditions).

Dosing protocols (commonly used; not endorsed)

Indication	Route	Dose	Frequency	Duration
Tendon/ligament injury (local)	SC near injury site	250-500 µg	1-2x daily	4-8 weeks
Systemic recovery	SC abdomen	250-500 µg	1-2x daily	4-8 weeks
Gut healing (IBD, NSAID damage)	Oral (if active)	250-500 µg	2x daily	4-12 weeks
Post-surgical recovery	SC	500 µg	1-2x daily	2-6 weeks

Reconstitution: typically 5 mg lyophilised peptide in 5 mL bacteriostatic water = 1 mg/mL; 250 µg dose = 0.25 mL = 25 units on an insulin syringe. Refrigerate after reconstitution; use within 30-60 days.

Genotype interactions

9p21.3 CDKN2B-AS1 (ANRIL) CC/GG risk genotypes for CAD: angiogenesis modulation has theoretically opposing effects in CAD — coronary collateralisation could benefit, but plaque neovascularisation could destabilise. No data either way. Cautious extrapolation: use the shortest effective duration; avoid chronic dosing in CAD-risk individuals.
COL1A1 Sp1 AA (collagen type I α1): this is the common genotype with normal type I collagen production; relevant to wound healing capacity. No direct interaction with BPC-157 mechanism but the underlying collagen substrate availability is normal.
GHR (growth hormone receptor) polymorphisms: BPC-157 upregulates GH-R on tendon fibroblasts (Chang 2014); individuals with GHR exon 3 deletion (GHRd3) have altered GH responsiveness which could theoretically interact with this mechanism. No published interaction.
VEGF -2578 / -1154 / -634 promoter polymorphisms: affect baseline VEGF expression; high-VEGF-baseline individuals theoretically need less BPC-157, low-VEGF individuals may have greater response. Not clinically actionable.
APOE ε3/ε4: brain-injury models suggest BPC-157 reduces lesion volume in TBI — relevant if traumatic head injury occurs; not a routine longevity indication.

Stack interactions

Commonly co-stacked (in self-experimentation):

TB-500 (Thymosin β-4) — see §2.2. The "BPC-157 + TB-500" stack is the most popular regenerative protocol in peptide forums; mechanistic rationale is complementary (BPC-157 → angiogenesis + GH-R upregulation; TB-500 → actin sequestration + cell migration + anti-inflammatory). No human evidence for synergy beyond mechanistic plausibility.
GHK-Cu — see §2.3. Often added for skin and connective tissue effects; copper-tripeptide upregulates SOD, MMP regulators, anti-inflammatory cytokines.
CJC-1295 / Ipamorelin — see §3.3, §3.4. Adds systemic IGF-1 elevation to the BPC-157 GH-R upregulation in tendon. Framework caution applies — this stack drives systemic mTOR.
Collagen / glycine / vitamin C — supports the collagen-synthesis substrate side of wound healing; framework-aligned (SUPPLEMENTS.md §2.1, §2.9).

Sourcing concerns

BPC-157 is one of the most commonly counterfeited peptides because demand is high. Specific concerns:

Identity verification. Independent mass spec testing has found "BPC-157" products that were truncated (missing 1-2 C-terminal residues), or actually different peptides.
Pentadecapeptide vs "BPC-157 Arginate" (PDA) confusion. PDA (see §2.4) is a different compound being marketed by some suppliers as a "more stable" or "more bioavailable" BPC-157. The pharmacology of PDA is even less established than that of BPC-157 — it has essentially zero peer-reviewed literature.
Bacteriostatic water reconstitution: always use benzyl-alcohol-preserved sterile water; do not reconstitute with tap water, saline from unsealed containers, or unsterile diluent.

Recommended verification: request COA (certificate of analysis) showing HPLC purity >98% and mass spec confirming molecular weight 1419.5 Da before any use.

Framework alignment

Aligned with: Pillar 5 (anabolic capacity / regenerative capacity preservation). Direct support for connective tissue repair, which is one of the most clinically frustrating limitations of aging — tendon and ligament healing slows dramatically after age 40 and is poorly responsive to conventional medicine.

Tension with: the cancer-promotion risk via VEGF/angiogenesis. Less of a framework tension than a general safety concern; the framework does not have a strong position on VEGF per se, but it has a strong position on not adding chronic growth-promoting signals in older adults.

Verdict: Tier 2 — Aligned, Context-Dependent. Defensible for short courses in acute musculoskeletal injury, IBD flares, post-surgical recovery, and gastritis. Hard to defend as a chronic longevity supplement. The human RCT evidence gap is large enough that anyone using BPC-157 should treat it as experimental self-medication, not as evidence-based therapy.

Evidence summary table

Claim	Evidence level	Notes
Accelerates rodent tendon healing	Strong (animal)	Multiple Sikiric papers; Krivic 2008 J Orthop Res; independent Taiwan replication (Chang 2011)
Accelerates rodent gut mucosal healing (IBD, ulcer models)	Strong (animal)	Multiple Sikiric papers; consistent across models
Reduces rodent NSAID-induced organ damage	Strong (animal)	Multiple Sikiric papers across gut, liver, brain
Upregulates VEGF in healing tissues (rodent)	Strong (animal)	Tkalcevic 2007, Hsieh 2017
Upregulates GH-receptor on tendon fibroblasts (in vitro)	Moderate	Chang 2014 J Appl Physiol
Orally bioavailable (systemic)	Contested	Sikiric group claims; no human PK data; mainstream pharmacology sceptical
Active locally in gut when given orally	Plausible	Local epithelial action explains gut data without systemic absorption
Effective for tendon healing in humans	Untested	No human RCTs; case reports only
Effective for IBD in humans	Untested	No human RCTs
Effective for TBI in humans	Untested	Rodent positive; no human data
Carries cancer-promotion risk via VEGF	Hypothesis (mechanistic)	No tumour-promotion seen in one rabbit VX2 model (Lojo 2016); inadequately studied
Acute safety in rodents at therapeutic doses	Strong	>1000-fold safety margin in rat studies
Long-term human safety	Untested	No long-term human data
Long-term carcinogenicity	Untested	No carcinogenicity studies

Key references

Sikiric P et al. (2010) "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol — foundational review from originating lab.
Sikiric P et al. (2017) "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing." Front Pharmacol — comprehensive mechanism review.
Sikiric P et al. (2018) "Brain-gut Axis and Pentadecapeptide BPC 157 Beneficial Effects on Various Stab and Crush Wound Effects in Skeletal Muscle and Tendon." Curr Pharm Des — musculoskeletal review.
Krivic A et al. (2008) "Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation." J Orthop Res — landmark tendon-healing rat study.
Chang CH et al. (2011) "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol — independent (Taiwan) replication; FAK-paxillin mechanism.
Chang CH et al. (2014) "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." J Appl Physiol — GH-R upregulation mechanism.
Cerovecki T et al. (2010) "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." J Orthop Res.
Tkalcevic VI et al. (2007) "Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression." Eur J Pharmacol — VEGF and Egr-1 mechanism.
Hsieh MJ et al. (2017) "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Vascul Pharmacol.
Vukojevic J et al. (2018) "Rapid and prolonged effect of stable gastric pentadecapeptide BPC 157 on traumatic brain injury." Neural Regen Res.
Veljaca M et al. (1995) "BPC-157 reduces trinitrobenzene sulfonic acid-induced colitis in rats." J Pharmacol Exp Ther — early IBD model.
Sebecic B et al. (1999) "Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits." Bone.
Lojo N et al. (2016) "Effects of diclofenac, L-NAME, L-arginine, and pentadecapeptide BPC 157 on gastrointestinal, liver, and brain lesions, failed anastomosis, and intestinal adaptation deterioration in 24 h-short-bowel rats." PLoS One.
Novinscak T et al. (2008) "Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat." Med Sci Monit.
Perovic D et al. (2019) "Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats." J Orthop Surg Res.
Sikiric P (1993) "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Acta Pharmacol Toxicol Hung — early human safety data (parent BPC, not BPC-157 per se).
Pollak M (2008) "Insulin and insulin-like growth factor signalling in neoplasia." Nat Rev Cancer — general context for IGF-1 / cancer concern relevant to growth-promoting peptides.
Sakr WA et al. (1993) "The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients." J Urol — occult cancer prevalence context.

Bottom line

BPC-157 is a synthetic pentadecapeptide with a unique three-decade rodent evidence base supporting tissue-healing efficacy across remarkably diverse contexts — tendon, ligament, gut, brain, liver, bone — but with essentially zero human RCT evidence and an under-investigated theoretical cancer-promotion mechanism via VEGF. Defensible as short-course (4-8 weeks) self-experimental therapy for acute musculoskeletal injury or IBD flares, with subcutaneous injection near the injury site being the most mechanistically supported route. Hard to defend as a chronic longevity supplement. Anyone using it should source from third-party-tested suppliers, use the shortest effective duration, avoid use during or after active malignancy, and treat the experience as experimental rather than evidence-based medicine.

2.2 TB-500 / Thymosin β-4

Tier: 2 — Aligned, Context-Dependent Class: 43-amino-acid actin-sequestering peptide; endogenous (highly conserved across species); TB-500 is a synthetic fragment of the full Tβ4 molecule Source: Endogenously expressed in nearly all cell types; concentrated in platelets and wound fluid

Mechanism summary: Sequesters G-actin (preventing premature polymerisation), promotes cellular migration, upregulates VEGF, anti-inflammatory effects, accelerates wound closure in rodent models including dermal, corneal, cardiac. Commonly stacked with BPC-157.

Framework alignment: Tier 2 — supports tissue repair (Pillar 5) but shares BPC-157's cancer-promotion theoretical concern via VEGF and via the promotion of cellular migration (which in dysplastic cells could promote metastasis). Banned by WADA in competitive sports.

Detailed analysis: pending.

2.3 GHK-Cu

Tier: 2 — Aligned, Context-Dependent Class: Copper-binding tripeptide (Gly-His-Lys-Cu²⁺) Source: Endogenously present in human plasma; declines ~60% between ages 20 and 60 (Pickart 2008)

Mechanism summary: Modulates >4000 genes (Pickart & Margolina 2018 Int J Mol Sci — gene-expression review); upregulates SOD, antioxidant defence; modulates MMPs; stimulates collagen, decorin, glycosaminoglycan synthesis; reduces TGF-β-driven fibrosis. Used topically (cosmetic, hair regrowth, wound healing) and subcutaneously (off-label).

Framework alignment: Strong mechanistic alignment with repair and antioxidant pillars; copper supply matters for cytochrome c oxidase (see SUPPLEMENTS.md §2.4). Caveat: chronic copper loading from injected GHK-Cu in non-deficient individuals could push systemic copper status above optimal — relevant for the copper:zinc balance discussion in SUPPLEMENTS.md §2.3 and §2.4.

Detailed analysis: pending.

2.4 Pentadeca-Arginate (PDA)

Tier: 2 — Aligned, Context-Dependent (provisional — pending more data) Class: Arginate salt of a BPC-157-like pentadecapeptide; recent introduction to the peptide market Status: Marketed as a "more stable" or "more bioavailable" BPC-157 variant

Mechanism summary: Claimed to share BPC-157's tissue-healing properties with improved stability. Peer-reviewed mechanistic literature is essentially absent — what exists is supplier marketing material and a handful of preprints.

Framework alignment: Same theoretical alignment as BPC-157 (regenerative); even more uncertainty because the evidence base is thinner than BPC-157's already-thin human evidence base. Provisional Tier 2 pending more data; could be reclassified upward or downward.

Detailed analysis: pending.

2.5 LL-37 / Cathelicidin

Tier: 2 — Aligned, Context-Dependent Class: 37-amino-acid antimicrobial peptide; the only human cathelicidin; cleaved from hCAP18 precursor Source: Endogenously produced by neutrophils, epithelial cells; production induced by vitamin D (VDR-dependent — relevant to SUPPLEMENTS.md §1.7)

Mechanism summary: Broad-spectrum antimicrobial against bacteria, viruses, fungi; immunomodulatory (chemotactic for neutrophils, monocytes, T-cells); promotes wound healing; clinically explored for chronic wound infections, biofilm-associated infections.

Framework alignment: Aligned with immune-defence aspect of healthspan; vitamin D status is the most important physiological lever for endogenous LL-37 (D3 → VDR → hCAP18 transcription). Synthetic LL-37 injection is a more aggressive intervention than supporting endogenous production via vitamin D + sun exposure.

Detailed analysis: pending.

2.6 Selank

Tier: 2 — Aligned, Context-Dependent Class: Synthetic heptapeptide; analogue of tuftsin with N-terminal extension Origin: Russian Academy of Medical Sciences, 1990s; widely used in Russia for anxiety disorders

Mechanism summary: Anxiolytic without sedation, cognitive enhancement, immunomodulatory; mechanism includes GABA-A modulation, BDNF upregulation, modulation of enkephalin peptidase. Intranasal administration most studied.

Framework alignment: Stress-reduction effects align with cortisol-reduction (framework views chronic cortisol as anti-thyroid, pro-catabolic); no growth-pathway concerns. Limited Western evidence base; bulk of human data is Russian-language literature.

Detailed analysis: pending.

2.7 Semax

Tier: 2 — Aligned, Context-Dependent Class: Synthetic heptapeptide; fragment of ACTH (4-7) with C-terminal extension Origin: Russian Academy of Medical Sciences; approved in Russia for stroke recovery

Mechanism summary: Nootropic / neuroprotective; upregulates BDNF and NGF; modulates dopaminergic system; some evidence in ischaemic stroke recovery in Russian trials.

Framework alignment: Neurotrophic support aligns with brain-healthspan goals; intranasal route bypasses systemic exposure. Same evidence-base caveat as Selank (Russian-dominated literature, limited Western replication).

Detailed analysis: pending.

2.8 DSIP (Delta Sleep-Inducing Peptide)

Tier: 2 — Aligned, Context-Dependent Class: Nonapeptide; originally isolated from rabbit cerebral venous blood during electrical-induced sleep state (Schoenenberger 1977) Status: Not commercially developed despite four decades of research

Mechanism summary: Promotes delta-wave (slow-wave) sleep; possibly stress-protective; mechanism poorly characterised after 40+ years — receptor unidentified.

Framework alignment: Sleep quality (particularly slow-wave sleep) is one of the highest-leverage longevity inputs; if DSIP genuinely augments SWS without rebound or tolerance, it would be highly framework-aligned. The unresolved mechanism after four decades is a concern — either the effect is real but mediated by a still-unknown receptor, or the effect is weak/inconsistent enough to have stymied mechanistic characterisation.

Detailed analysis: pending.

2.9 Thymalin

Tier: 2 — Aligned, Context-Dependent Class: Polypeptide complex extracted from calf thymus (Khavinson school product) Status: Available in Russia and some Eastern European markets

Mechanism summary: Claimed to restore T-cell function; mechanistically presumed similar to thymosin α-1 but the preparation is a complex (not a single defined peptide) which complicates pharmacology.

Framework alignment: Conceptually aligned (immunosenescence reversal) but evidence base much weaker than thymosin α-1 because Thymalin is a complex extract rather than a defined molecule. Western replication essentially absent.

Detailed analysis: pending.

Tier 3 — Mixed / Complicated

Framework consistency call for §3.1–3.6 (the GH/GHRH/GHRP/GHS class): All of these peptides (and the non-peptide MK-677) elevate GH and downstream IGF-1. Mainstream longevity culture treats this favourably — restoring "youthful GH/IGF-1 levels." The bioenergetic framework's position is more nuanced: acute pulsatile GH (which is how endogenous GH secretion works) coupled to anabolic windows (resistance training, post-prandial) supports lean-mass preservation (Pillar 5) and is desirable in older adults losing muscle. Chronic systemic IGF-1 elevation drives mTOR signalling indiscriminately across all tissues including any incipient neoplastic clones, and is epidemiologically associated with increased cancer incidence (Pollak 2008 Nat Rev Cancer; mirror image of Laron dwarfism — Guevara-Aguirre 2011 Sci Transl Med). The mainstream-longevity stack that combines GH secretagogues with rapamycin to block mTOR is internally incoherent. The framework's position: peptides in this class are Tier 3 (mixed) rather than Tier 1 or Tier 2 because of this growth-axis tension; specific clinical use cases (HIV lipodystrophy for tesamorelin, adult GHD for sermorelin) can be defensible, but the "anti-aging boost" use case is harder to defend on framework grounds.

3.1 Tesamorelin

Tier: 3 — Mixed / Complicated Class: GHRH (1-44) analogue with N-terminal modification for protease resistance Status: FDA-approved (Egrifta) for HIV-associated lipodystrophy

Mechanism summary: Restores pulsatile GH secretion via pituitary GHRH receptor; reduces visceral adipose tissue (5-20% reduction in HIV lipodystrophy trials); modest cognitive benefit shown in MCI (Baker 2012 Arch Neurol).

Framework alignment: Tier 3 — most rigorous human evidence in the GH-axis class because it's FDA-approved; the visceral fat reduction is mechanistically aligned (visceral adipose tissue is metabolically harmful, framework-anti); the systemic IGF-1 elevation is the framework concern. Use case-dependent — visceral fat in a metabolically unhealthy older adult vs general anti-aging use are very different.

Detailed analysis: pending.

3.2 Sermorelin

Tier: 3 — Mixed / Complicated Class: GHRH (1-29) analogue Status: FDA-approved historically for paediatric GHD (withdrawn from US market 2008 commercially; compounded versions still prescribed)

Mechanism summary: Stimulates pulsatile GH release via GHRH receptor; preserves negative feedback (somatostatin still works) so less supraphysiological than exogenous GH.

Framework alignment: Same Tier 3 logic as tesamorelin — preserved feedback is a safety advantage over exogenous recombinant GH; chronic IGF-1 elevation remains the framework concern.

Detailed analysis: pending.

3.3 CJC-1295 (with and without DAC)

Tier: 3 — Mixed / Complicated Class: Modified GHRH (1-29) analogue; DAC variant has a drug-affinity-complex tag conferring 7-8 day half-life via albumin binding Status: Research chemical; not FDA-approved

Mechanism summary: Same receptor as sermorelin/tesamorelin (GHRH-R); modifications confer protease resistance and (with DAC) extended half-life. The DAC variant produces continuous (rather than pulsatile) GH/IGF-1 elevation — this is the central framework concern, because pulsatile and continuous GH have different physiological consequences (pulsatile preserves negative feedback, continuous suppresses it and produces more sustained IGF-1 elevation).

Framework alignment: Tier 3 — CJC-1295 without DAC (mod-GRF 1-29, short half-life) is the framework-preferable form because it preserves pulsatility; CJC-1295 with DAC should be avoided on framework grounds (continuous IGF-1 drive is the worst-case scenario for the cancer-promotion concern).

Detailed analysis: pending.

3.4 Ipamorelin

Tier: 3 — Mixed / Complicated Class: Selective ghrelin receptor (GHS-R1a) agonist; pentapeptide Status: Research chemical; was in Phase 2 clinical trials for post-operative ileus (Helsinn) — development discontinued

Mechanism summary: GH secretagogue acting via ghrelin receptor on somatotrophs; more selective than older GHS like GHRP-2 and GHRP-6 (less cortisol and prolactin elevation). Commonly stacked with CJC-1295 (no DAC) for synergistic pulsatile GH release.

Framework alignment: Tier 3 — same GH-axis concern; ipamorelin's selectivity (minimal cortisol/prolactin) is a safety advantage over GHRP-2/6 but does not address the IGF-1/cancer concern. The CJC-1295-no-DAC + ipamorelin stack is the framework-preferable form within this class because it produces pulsatile rather than continuous GH elevation.

Detailed analysis: pending.

3.5 Hexarelin

Tier: 3 — Mixed / Complicated Class: Hexapeptide GHS; older-generation Status: Research chemical

Mechanism summary: Potent GHS; some evidence of cardioprotective effects independent of GH (CD36-mediated) but elicits more prolactin and cortisol elevation than ipamorelin; tachyphylaxis (desensitisation) develops with chronic use.

Framework alignment: Tier 3 — within the GHS class, hexarelin is less preferable than ipamorelin because of the cortisol/prolactin elevation and tachyphylaxis; cardioprotective claims are intriguing but not well-replicated.

Detailed analysis: pending.

3.6 MK-677 / Ibutamoren

Tier: 3 — Mixed / Complicated Class: Non-peptide oral GHS-R1a agonist (included with note — technically not a peptide, but mechanistically and culturally grouped with the GHS class) Status: Research chemical; failed Alzheimer's trial; never approved despite Phase 3 testing

Mechanism summary: Oral, long-acting (24-hour half-life) ghrelin receptor agonist; sustained 24-hour elevation of GH and IGF-1; appetite stimulation (ghrelin mimicry); fluid retention; insulin resistance; sleep architecture changes (more slow-wave sleep but also more fragmentation).

Framework alignment: Tier 3 leaning toward Tier 4. MK-677 is the worst framework match in the GHS class because (a) it produces sustained (24-hour) IGF-1 elevation rather than pulsatile, (b) it induces insulin resistance (anti-framework), (c) it causes water retention often misread as muscle gain, (d) appetite drive can drive overeating, (e) it's oral and easy to take chronically, which compounds the cancer-promotion timeline concern.

Detailed analysis: pending.

3.7 Cerebrolysin

Tier: 3 — Mixed / Complicated Class: Porcine brain-derived neuropeptide preparation (complex, not a single defined peptide); contains low-MW peptides and free amino acids Status: Approved in many European, Asian, and Latin American countries for stroke recovery, vascular dementia, TBI; not FDA-approved

Mechanism summary: Claimed BDNF/NGF-mimetic activity; some evidence in acute ischaemic stroke (Cochrane review found modest benefit), MCI, and TBI. Complex undefined composition makes mechanistic characterisation difficult.

Framework alignment: Tier 3 — neurotrophic support aligns with brain-healthspan, but the undefined composition is a concern for both reproducibility and safety. Porcine origin raises infection-transmission concerns (theoretical).

Detailed analysis: pending.

3.8 PT-141 / Bremelanotide

Tier: 3 — Mixed / Complicated Class: Synthetic cyclic heptapeptide; melanocortin receptor agonist (MC1R, MC3R, MC4R) Status: FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women

Mechanism summary: Central nervous system mechanism via MC4R; pro-erectile and pro-libido effects in both sexes; bypasses peripheral vascular mechanisms (works in some PDE5-inhibitor non-responders).

Framework alignment: Mostly orthogonal to the bioenergetic framework. Side effects (nausea, hyperpigmentation, blood pressure elevation) and the unclear long-term safety of chronic MC4R agonism warrant the Tier 3 placement. Use case-specific (sexual dysfunction) rather than a general longevity peptide.

Detailed analysis: pending.

3.9 Kisspeptin-10

Tier: 3 — Mixed / Complicated Class: Decapeptide; KISS1R agonist Status: Research chemical; under clinical investigation for hypothalamic hypogonadism

Mechanism summary: Stimulates hypothalamic GnRH neurons → LH/FSH → gonadal sex hormone production; preserves HPG axis pulsatility unlike exogenous testosterone or HCG; emerging research interest for hypothalamic hypogonadism in both sexes, sexual response, fertility.

Framework alignment: Tier 3 leaning Tier 2 — kisspeptin works at the top of the HPG axis (preserves downstream regulation), which is more physiologically respectful than exogenous testosterone replacement or HCG. Limited human safety data is the limiting factor.

Detailed analysis: pending.

3.10 Melanotan I (Afamelanotide / Scenesse)

Tier: 3 — Mixed / Complicated Class: α-MSH analogue; potent MC1R agonist Status: FDA-approved (Scenesse) for erythropoietic protoporphyria

Mechanism summary: Stimulates eumelanin production via MC1R; provides UV-protective tanning; medical indication is genuine (EPP patients have life-disrupting photosensitivity). Off-label cosmetic use for tanning is widespread.

Framework alignment: Tier 3 — for genuine medical indication (EPP, vitiligo, photosensitivity disorders) the risk-benefit is favourable; for cosmetic tanning the long-term melanocortin-axis effects and the masking of melanoma warning signs (new dark moles harder to distinguish from drug-induced pigmentation) are concerns. Sunlight exposure (which the framework supports — see SUPPLEMENTS.md §1.7 vitamin D / sunlight discussion) for non-photosensitive individuals does not need a melanocortin agonist.

Detailed analysis: pending.

Tier 4 — Avoid

4.1 Melanotan II

Tier: 4 — Avoid Class: Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R); cyclic heptapeptide Status: Research chemical; never approved for any indication

Mechanism summary: Same tanning effect as Melanotan I but with potent MC3R/MC4R/MC5R co-activation → sexual arousal, appetite suppression, blood pressure changes, gastrointestinal effects (nausea), hyperpigmentation including darkening of existing nevi.

Framework alignment: Avoid. Non-selective melanocortin agonism is a much more aggressive intervention than Melanotan I; reports of new melanoma in long-term users (causality unestablished but biologically plausible given the masking effect on nevus surveillance); cosmetic-only use case does not justify the safety profile. PT-141 (§3.8) is the more selective, FDA-approved alternative if the goal is sexual function rather than tanning.

Detailed analysis: pending.

4.2 Khavinson School Bioregulators — Methodological Overview (Epitalon, Vesugen, and the wider "peptide bioregulator" pharmacopoeia)

Tier: 4 — Avoid (with caveat that the evidence question is genuinely unresolved) Class: Short peptides (2-4 amino acids typically) developed by Vladimir Khavinson's group (St Petersburg Institute of Bioregulation and Gerontology, Russia) over ~40 years; claimed to be organ-specific bioregulators (e.g., Epitalon → pineal; Vesugen → vascular; Pinealon → CNS; Cortagen → cortical; Prostamax → prostate) Status: Sold extensively as research chemicals; some marketed in Russia and Eastern Europe as supplements Scope of this section: Methodological and historical critique of the whole peptide-bioregulator programme. For the most prominent individual peptide deep dive, see §4.3 Pinealon. Epitalon (Ala-Glu-Asp-Gly), Vesugen (Lys-Glu-Asp), Cortagen (Ala-Glu-Asp-Pro), and the remainder of the "cytogen" series share the same methodological issues outlined below and are not individually expanded.

The two distinct Khavinson series. The Khavinson programme has two layers:

Cytomedines — crude polypeptide extracts from animal organs (calf thymus → Thymalin / Vilon; pineal → Epithalamin; prostate → Prostatilen). These are heterogeneous extracts containing many peptides, proteins, and small molecules; framework analysis of any cytomedine is essentially the analysis of an unfractionated tissue extract.
Cytogens — short synthetic peptides (typically dipeptides, tripeptides, tetrapeptides) intended as "active substance" analogues of the cytomedines. Epitalon, Pinealon, Vesugen, Cortagen all fall here. The cytogen concept is that 2-4 amino-acid sequences carry the "bioregulatory information" of the parent extract — a claim that is mechanistically the core of the controversy.

Mechanism summary (claimed). The Khavinson group's central hypothesis (Khavinson 2011 Neuro Endocrinol Lett; Khavinson 2014 Biochemistry Moscow Supplement Series B) is that short peptides act as site-specific transcription factor mimetics — they enter cells, traverse the nuclear envelope, bind specific promoter regions of organ-relevant genes (claimed via direct interaction with the major groove of duplex B-DNA), and thereby regulate organ-specific gene expression. Specific claims include Epitalon upregulating telomerase, restoring pineal melatonin secretion, normalising circadian rhythm, and extending lifespan in mice and (in their cohort studies) reducing mortality in elderly Russian subjects.

Mechanism summary (skeptical reading). Four convergent biophysics objections apply across the whole cytogen series and are spelled out in detail for Pinealon in §4.3 (information theory; serum peptidase half-life; cell penetration; affinity verification). In brief: a 2-4 amino acid peptide has insufficient information content to specify a unique site in a 3 Gb genome; serum peptidase degradation half-life is short (minutes); the proposed cell-penetration and nuclear-import behaviour conflicts with established CPP and nuclear-localisation-signal motif requirements; and the proposed DNA binding affinity has not been confirmed by the standard biophysics methods (ITC, SPR, X-ray crystallography, NMR, cryo-EM).

Replication landscape. The Khavinson-group corpus is large (Khavinson lists ~400 publications on cytogens since 1980) but the corpus is concentrated within the St Petersburg Institute of Bioregulation and Gerontology and a small network of collaborating Russian institutes. Independent replication outside the Khavinson network is thin. Standard PubMed search returns essentially no Western-authored RCT testing any cytogen with adequate blinding, registration, and pre-specified endpoints. The "human cohort" mortality data underpinning Epitalon's longevity claims (Khavinson 2003 Neuro Endocrinol Lett) was unblinded, non-randomised in the modern sense, and conducted entirely within the Khavinson institutional network. This is not by itself proof of fabrication — Russian biomedical institutions operated under different methodological norms, particularly during the late Soviet and early post-Soviet period — but it does mean the cytogen evidence base has not survived the standard external replication that grounds Western pharmacology.

Framework alignment. The mechanistic claims, if true, would be framework-aligned (melatonin restoration → circadian → mitochondrial; telomerase activation → replicative reserve; organ-specific maintenance of pineal, thymic, vascular function). The mechanistic plausibility and evidence-quality concerns are large enough to recommend avoidance until independent Western replication appears. Honest assessment: this is one of the largest evidence-quality gaps in the entire peptide field. Tier 4 placement reflects the evidence-base failure and the mechanism implausibility as claimed, not certainty that the compounds are biologically inert. It is entirely possible that some cytogens have real effects through mechanisms that are not the site-directed DNA-binding mechanism the Khavinson group proposes — e.g., free-amino-acid pool effects after rapid proteolysis, transient receptor effects analogous to neuropeptide signalling, or nonspecific chaperone-mimetic effects. None of those alternative mechanisms would underwrite the specific claims of organ-targeted gene regulation.

For the most-discussed individual cytogen (Pinealon), see §4.3.

4.3 Pinealon (Glu-Asp-Arg / EDR)

Tier 4 placement rationale: Pinealon is placed in Tier 4 on two convergent grounds. First, an evidence-quality failure: there are no large independent Western RCTs, the human evidence base is dominated by small unblinded Russian trials from the originating institute, and the rodent literature is replicated thinly outside the Khavinson network. Second, and more importantly, a mechanism-plausibility failure: the central claim that a tripeptide performs site-directed promoter binding to organ-specific genes is on its face inconsistent with basic information theory, with serum peptidase kinetics, and with the established biophysics of cell-penetrating peptides. Tier 4 here does not assert that Pinealon is biologically inert — it asserts that the mechanism as claimed is implausible and the evidence base is too weak to recommend use. A genuinely positive result from a well-powered blinded Western RCT in age-related cognitive decline would warrant re-evaluation; that result does not currently exist.

Discovery and structure

Pinealon is a synthetic tripeptide with the sequence:

Glu-Asp-Arg
 E   D   R

Molecular weight 418.4 Da. The peptide carries one positive charge (Arg side chain, pKa ~12) and two negative charges (Glu γ-carboxyl pKa ~4.3, Asp β-carboxyl pKa ~3.9) at physiological pH — net charge approximately −1. No hydrophobic residues; no cationic clusters; no canonical cell-penetrating-peptide signature.

Pinealon was developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology (Институт биорегуляции и геронтологии) in the early-to-mid 2000s, with first published characterisations in the Russian literature around 2007-2008 and the first widely cited English-language Khavinson-group papers around 2010-2012. It belongs to the "cytogen" subset of Khavinson peptides — the short synthetic 2-4mers developed as putative active-substance analogues of the older "cytomedine" organ extracts (see §4.2 for the cytomedine vs cytogen distinction).

The "Pinealon" trade name derives from the claimed pineal/CNS bioregulatory activity. The Khavinson-group framing is that Pinealon is the cytogen analogue of the cytomedine Epithalamin (a polypeptide extract from bovine pineal gland), in the same way that Epitalon (Ala-Glu-Asp-Gly) is also claimed to be an Epithalamin-derived cytogen. The relationship between Pinealon and Epitalon is therefore conceptually overlapping in the Khavinson framework, with Pinealon framed as more CNS/cortical and Epitalon as more pineal/circadian — though both are claimed to derive from the same parent tissue extract, which immediately raises the question of how two different short peptides extracted from the same source can have distinct organ-specific effects.

Proposed mechanisms — the Khavinson model

Khavinson and collaborators have published a consistent mechanistic model across roughly two decades, summarised here at face value:

Site-directed DNA binding. The central claim: Pinealon (and other cytogens) penetrate the cell membrane, traverse the nuclear envelope, and bind directly to promoter regions of specific genes in the major groove of duplex B-DNA. Khavinson 2011 (Neuro Endocrinol Lett) and Khavinson 2014 (Biochemistry Moscow Supplement Series B) propose this is sequence-specific — i.e., Pinealon's E-D-R sequence "matches" a specific subset of promoter triplets and thereby regulates a specific subset of organ-relevant genes. This model is sometimes called "peptide-DNA bioregulation."
Transcription factor mimicry. A corollary claim: Pinealon acts as a minimal transcription factor, competing with or mimicking endogenous TF binding to specific promoter elements. The proposed mechanism mirrors classical Brenner-Crick-style coding logic — that a short sequence encodes specific binding information.
Organ-specific gene regulation. The cytogen programme predicts that each short peptide upregulates a defined gene-expression programme tied to a specific organ — Pinealon → CNS/cortical maintenance genes; Epitalon → pineal/melatonin-axis genes; Vesugen → vascular endothelial genes; and so on. This is presented as the explanation for why a small library of short peptides can cover an entire organ-system pharmacopoeia.
Cell-penetrating peptide behaviour. Implicit in the model is the assumption that Pinealon crosses the plasma membrane unaided by transport machinery, in sufficient quantity to reach intranuclear effective concentrations. Khavinson group papers occasionally reference rhodamine- or fluorescein-labelled cytogen tracking experiments to support this; the labelled-tracer experiments have not been independently reproduced in Western labs at the level of rigour required to distinguish actual cytoplasmic/nuclear localisation from artifacts of fixation, label dissociation, or non-specific surface binding.
Downstream effects — claimed: upregulation of antioxidant defence (SOD, GPx, catalase), reduction of apoptotic markers (caspase-3, p53 phosphorylation) in stressed neurons, normalisation of neurotransmitter balance (serotonin, dopamine, norepinephrine) in aged rats, improvement of memory and learning in passive-avoidance and Morris water maze paradigms.

Mechanism critique — the skeptical reading

There are four convergent biophysics objections to the Khavinson cytogen model as it specifically applies to Pinealon. None is fatal in isolation; together they constitute a strong case that the central mechanistic claim is not what is happening, even if some downstream biological effect is real.

Objection 1: Information theory rules out 3-mer site-specific DNA binding.

A 3-mer drawn from the 20 proteinogenic amino acids has 20³ = 8,000 possible sequences. The information content of choosing one specific 3-mer is log₂(8,000) ≈ 13 bits.

A typical transcription-factor binding site in eukaryotic DNA is 6-12 base pairs and must be specified uniquely (or near-uniquely) within a ~3 × 10⁹ bp genome. The information required to locate a single unique site in 3 Gb is log₂(3 × 10⁹) ≈ 31.5 bits. Real transcription factors achieve specificity using DNA-binding domains of ~50-150 amino acids that contact 6-12 bp through a network of base-specific and phosphate-backbone contacts, with binding free energies of −10 to −15 kcal/mol distributed across multiple residue-base hydrogen bonds, salt bridges, and shape readout. The information capacity of a 150-residue protein domain is more than sufficient to specify 31.5 bits of binding preference; the information capacity of a 3-mer (13 bits) is intrinsically insufficient by a factor of >2× in bits — and worse than that in practice because the available "specificity surface" of a 3-mer is only ~3-5 base-contacting positions at most.

In other words, a tripeptide cannot, even in principle, bind a unique site in the genome through direct sequence-specific readout — there are not enough sequence-specifying degrees of freedom in the peptide to discriminate the target site from the ~10⁶-10⁷ alternative sites of similar local geometry that exist by chance in 3 Gb of DNA. Even if Pinealon binds DNA at all, the binding cannot be sequence-directed in the sense the Khavinson model claims. This is the central, and least negotiable, objection.

The standard counter-argument the Khavinson group offers is that the peptide binds with low absolute affinity to many sites simultaneously and exerts an aggregate effect across many promoters. That is a coherent alternative model — but it is not the "site-directed organ-specific gene regulation" model the cytogen literature actually claims, and it does not predict organ-specific effects.

Objection 2: Serum peptidase kinetics make systemic delivery of intact peptide implausible.

Free linear peptides in mammalian plasma face an extensive set of degrading enzymes — aminopeptidases (cleaving from the N-terminus), carboxypeptidases (cleaving from the C-terminus), endopeptidases (cleaving internal bonds), and dipeptidyl peptidases (cleaving N-terminal dipeptides). Pinealon's E-D-R sequence has no protection against any of these classes: the N-terminal Glu is a substrate for aminopeptidase A (preferentially cleaves acidic residues); the C-terminal Arg is a high-affinity substrate for carboxypeptidase N (which has strong specificity for basic C-termini and is abundant in plasma); the central E-D bond is a substrate for multiple endopeptidases.

Experimentally measured plasma half-lives of unprotected short peptides typically fall in the range of 1-10 minutes. Khavinson-group claims of intact systemic delivery after SC, IM, or oral administration have not been confirmed by independent Western pharmacokinetic studies with adequate analytical methods (LC-MS/MS quantification of intact parent peptide vs metabolites). What the rodent labelled-tracer experiments most likely demonstrate is amino acid delivery to tissues following peptide hydrolysis — i.e., free Glu, free Asp, and free Arg entering the systemic free amino-acid pool — not delivery of intact tripeptide.

This matters because the entire "organ-specific gene regulation" claim requires the intact tripeptide to reach intranuclear concentrations sufficient for the proposed DNA contact. If only free amino acids reach the tissue, no peptide-specific mechanism can be operating, and any biological effect would be a free-amino-acid effect — which would not be peptide-specific and would be identical across all cytogens with the same amino-acid composition.

Objection 3: Pinealon lacks the structural motifs required for cell penetration.

Cell-penetrating peptides (CPPs) are a well-characterised class (TAT 47-57, penetratin, polyarginine R8/R9, MAP, transportan) with shared features: predominantly cationic (multiple Arg or Lys residues — typically 5-9), often amphipathic, often α-helical or capable of forming helical structures upon membrane interaction. The minimum charge density for reliable CPP behaviour is several positive residues clustered in a short window — polyarginine R8 is considered close to the minimum effective oligoarginine.

Pinealon has one Arg, balanced against two acidic residues (Glu, Asp). Net charge is approximately −1 at physiological pH. There are no hydrophobic residues to enable membrane partitioning. There is no helical propensity in a tripeptide of this composition. By every established structural criterion for cell penetration, Pinealon should not cross the plasma membrane in any pharmacologically meaningful quantity. Khavinson-group claims of intracellular and intranuclear localisation conflict with the biophysics literature on what makes a peptide cell-permeable; the conflict is not addressed in the cytogen literature.

Objection 4: The proposed DNA-binding affinity has not been confirmed by standard biophysics.

If Pinealon binds B-DNA with the affinity and specificity the Khavinson model requires, that binding should be demonstrable by isothermal titration calorimetry (ITC) measuring binding enthalpy and stoichiometry; by surface plasmon resonance (SPR) measuring on- and off-rates; by X-ray crystallography or cryo-EM of the peptide-DNA complex; or by NMR resolving the peptide chemical-shift perturbation upon DNA binding. These are standard tools that have characterised peptide-DNA interactions for decades for compounds where such interactions are real (e.g., minor-groove binders like distamycin, intercalators like daunorubicin, polyamides). The Khavinson cytogen literature does not contain rigorous biophysics of this kind for Pinealon. The closest published evidence is computational docking and circular dichroism studies, neither of which can confirm specific high-affinity binding.

Putting the four objections together: the claim "Pinealon binds specific gene promoters and regulates organ-specific gene expression" requires (a) intact peptide to reach the tissue, (b) intact peptide to enter the cell, (c) intact peptide to enter the nucleus, (d) intact peptide to bind a specific DNA site with sufficient affinity and information content to discriminate that site from background. Each of these four steps is implausible on independent grounds. The conjunction is implausibility-squared.

What might actually be happening if Pinealon produces real biological effects:

Free amino-acid effects after rapid hydrolysis (most likely null or marginal at the doses used).
Transient receptor effects analogous to short neuropeptide signalling (possible in principle but not characterised).
Effects from peptide aggregates, contaminants, or formulation excipients in the actual product (a real concern given the sourcing landscape).
Placebo and observer-bias effects in unblinded studies (likely contribution to the human evidence).
Nonspecific stress-protective effects via free arginine entry into the NO-substrate pool (Arg is a substrate for nitric oxide synthase; downstream free Arg from peptide hydrolysis could have a small NO-related effect).

None of these alternative mechanisms supports the specific organ-targeted gene-regulation narrative.

Animal evidence

The Khavinson group has published a body of rat studies on Pinealon in cognitive and ischemic injury models. The strongest claims and the weakest methodology elements:

Strongest claims (rodent):

Cognitive protection in aged rats. Khavinson-group studies (Khavinson 2011; Arutjunyan 2010 Bull Exp Biol Med) report improvement in passive-avoidance learning, Morris water maze performance, and exploratory behaviour in aged rats treated with Pinealon vs saline controls, with effect sizes commonly reported in the 20-50% range on continuous behavioural endpoints.
Neuroprotection in hypoxia/ischemia models. Several rat studies report reduced neuronal apoptosis (TUNEL-positive cell count), reduced caspase-3 activation, and preserved hippocampal CA1 cell density after acute hypoxic exposure or middle cerebral artery occlusion when Pinealon is given before or shortly after the insult.
Antioxidant effect. Reports of increased SOD, catalase, and glutathione activity in cortex and hippocampus of treated rats vs controls.
Prenatal hypoxia model. Arutjunyan-group studies report developmental protection of rat pups exposed in utero to maternal hypoxia when dams are treated with Pinealon — a model the Khavinson programme has used as a flagship demonstration of cytogen activity.

Weakest methodology elements:

Single-lab concentration. As with the broader cytogen literature, the great majority of positive Pinealon rodent data comes from the St Petersburg Institute or close collaborators. Independent replication outside the network is sparse.
Blinding and randomisation. Pre-2010 Khavinson-group rodent papers often do not document blinded outcome assessment in the way modern preclinical reporting standards (ARRIVE guidelines, 2010 onwards) require. Behavioural endpoints are particularly vulnerable to observer bias.
Dose-response curves. Often a single dose is tested vs control rather than a full dose-response, which makes it difficult to distinguish a real pharmacological effect from a noise-floor positive result.
Mechanism of action verification. The papers proposing antioxidant or anti-apoptotic mechanisms typically measure downstream markers (SOD activity, caspase-3 cleavage) without testing the upstream gene-regulation claim with ChIP-seq, ATAC-seq, or RNA-seq — the modern tools that would test whether Pinealon actually binds promoters and changes transcription as the model predicts.
Positive control absence. Pinealon is typically compared to saline rather than to an active comparator (e.g., a known neuroprotectant), which makes it impossible to calibrate the effect size against established benchmarks.

Human evidence — the critical gap

There are no large Western RCTs of Pinealon. The human evidence base consists of:

A small number of Russian-language publications from the Khavinson institute and collaborating Russian clinical centres, reporting cognitive improvement in elderly subjects with mild cognitive impairment or post-stroke cognitive decline. Sample sizes typically 30-100; blinding inconsistent or absent; outcome measures heterogeneous (MMSE, Russian cognitive batteries); no pre-registration.
Inclusion of Pinealon in some Khavinson-group cohort longevity studies (Korkushko 2011; analogous to Epitalon cohort work), which report all-cause mortality differences in elderly Russian cohorts — these have the same methodological issues as the Epitalon cohort work: unblinded administration, non-randomised assignment, healthy-user bias.

What does not exist:

No Cochrane review of Pinealon.
No FDA filings, no EMA filings, no PMDA filings.
No registered Phase 2 or 3 trials on ClinicalTrials.gov.
No independent Western academic medical centre programme.
No publications in high-impact Western neurology, geriatrics, or pharmacology journals.

The contrast with the cognitive-enhancement and neuroprotection literature for established compounds (e.g., the donepezil RCT base, the citicoline stroke trials, the cerebrolysin meta-analyses) is stark: those compounds have multi-thousand-subject blinded randomised trials with pre-specified endpoints. Pinealon does not.

Bioavailability problem

The tripeptide stability question is the same one that defeats the broader cytogen mechanism: an unprotected linear tripeptide given orally is degraded by gastric pepsin (cleaves at hydrophobic residues — Pinealon has none, providing some protection from pepsin specifically, but not from the general acidic-pH peptide hydrolysis environment), intestinal brush-border peptidases (cleave broadly), and serum aminopeptidase/carboxypeptidase activity within minutes after absorption.

Routes claimed by Khavinson-group and downstream practitioner literature:

Subcutaneous injection — most common route in the rodent literature and the practitioner peptide subculture. Bypasses GI peptidases but does not protect from plasma peptidases; intact tripeptide half-life in circulation is expected to be minutes.
Intranasal administration — claimed to bypass blood-brain barrier via olfactory and trigeminal nerve routes. Intranasal delivery of small peptides can achieve some CNS penetration (the route has legitimate pharmacology for oxytocin, insulin, and others), but the fraction of administered dose that actually reaches brain tissue intact is typically <1%. Pinealon-specific intranasal PK has not been rigorously characterised in humans.
Sublingual administration — claimed to bypass first-pass GI degradation. The buccal mucosa is permeable to small lipophilic molecules; permeability to charged hydrophilic peptides is poor.
Oral administration — claimed by the Khavinson group to be effective despite the obvious objection that no intact peptide should survive the GI tract. The proposed explanation involves protected uptake by enterocytes via PEPT1 (the di/tripeptide transporter) — PEPT1 does transport tripeptides, so the uptake claim is not implausible, but onward systemic delivery of intact peptide vs hydrolysis at the enterocyte basolateral membrane has not been resolved.

Practical pharmacokinetic bottom line: none of the proposed routes has been shown to deliver intact Pinealon to CNS target tissue at concentrations sufficient for the proposed DNA-binding mechanism. The most parsimonious reading is that any systemic biological effect observed after administration is mediated by hydrolysis products (free amino acids) or by local effects at the administration site (intranasal trigeminal/olfactory; SC tissue) rather than by intact peptide acting at a CNS receptor or nuclear target.

Pinealon is currently being promoted in the longevity peptide subculture (Twitter/X, biohacker forums, Russian peptide vendors, some podcast circuits) on the basis of claims that substantially exceed the evidence base. Typical framings include "FDA-equivalent approved in Russia" (it is not approved in any pharmacopoeia in the sense Western readers will understand), "telomerase activator" (this claim properly belongs to Epitalon, not Pinealon, and is itself weakly evidenced), "proven to extend lifespan" (no RCT supports this), and "third-generation Khavinson peptide" (a marketing label, not a scientific category).

This document does not dismiss the underlying research question — whether short peptides can produce real biological effects in age-related cognitive decline is an open and legitimate scientific question, and the Khavinson programme has produced a body of work that warrants serious independent evaluation rather than reflexive rejection. The framing concern is specifically about the mismatch between what social media promotion claims for Pinealon (proven, safe, effective, FDA-equivalent) and what the evidence base actually supports (small unblinded trials from a single institutional network; mechanism that is not biophysically plausible as claimed; no Western RCT validation). Apply the same evidence rigour to Pinealon that you would apply to any other compound that arrived via the same channel; the Twitter discourse is not a substitute for that rigour.

Sourcing concerns

The Pinealon supply chain is dominated by Russian peptide vendors with limited or no third-party quality control. Specific issues:

Identity verification. Independent mass-spec testing of "Pinealon" products is essentially absent in the public literature. Whether the labelled product actually contains Glu-Asp-Arg, contains a different peptide, contains a mixture, or contains free amino acids is not verifiable from the product label or vendor COA alone (vendor COAs are routinely fabricated in the grey-market peptide supply chain).
Batch consistency. Between-batch variability in peptide content, purity, and impurity profile is high in the Russian peptide market.
Contamination risk. Endotoxin (LPS) contamination is a routine concern in any non-pharmaceutical-grade peptide intended for injection. LPS at low microgram/dose levels can produce systemic inflammation and is undetectable by visual inspection of the reconstituted solution.
Legal status. Pinealon is not a controlled substance in most jurisdictions but is also not an approved drug in any Western pharmacopoeia. Sale "for research use only" is the typical legal framing, with possession and personal use in a grey zone that varies by jurisdiction.
Counterfeiting. Products marketed as Pinealon may be misidentified, mislabelled, contain different cytogens, or be entirely inactive.

Safety profile

What is known:

The Khavinson-group rodent toxicology shows no acute toxicity at doses orders of magnitude above the proposed therapeutic range. Free Glu, Asp, and Arg (the hydrolysis products) are normal dietary amino acids with well-characterised safety profiles at the doses delivered.
The Khavinson-group human cohort and small-trial data report no serious adverse events. Within the limitations of small unblinded trials, no specific organ toxicity signal has emerged.

What is not known:

Long-term safety in healthy adults using Pinealon as a continuous "longevity" intervention. The cumulative effect of chronic SC injection of any peptide can include local injection-site reactions, immunogenicity (anti-peptide antibody development), and unknown long-term consequences.
Contamination risk from the supply chain — endotoxin exposure, residual synthesis impurities, undisclosed adulterants — is unquantified for any specific product.
Interactions with concurrent neurological or psychiatric medication.
Effect in individuals with active malignancy. The Khavinson programme's claims of pro-mitotic and pro-regenerative effects, if real, would carry the same theoretical cancer-promotion concern that applies to any growth-promoting peptide, though no specific Pinealon tumour-promotion data exists either way.

Genotype interactions

Direct genotype interactions are minimal given the uncertain mechanism, but the following are worth noting:

APOE ε4 carriers. Any neuroprotective claim is directly relevant to APOE ε4-associated cognitive decline risk. The challenge is that the evidence supporting a real neuroprotective effect of Pinealon in humans is thin. APOE ε4 carriers who are inclined toward Pinealon for cognitive protection have a better-evidenced alternative stack — mercury/aluminium detoxification (per the dedicated detoxification protocols), B-vitamin methylation support (SUPPLEMENTS.md §1.2), VITACOG-protocol homocysteine reduction, omega-3 from whole fish, mitochondrial support stack (CoQ10, taurine, magnesium, creatine), and seed-oil avoidance. Pinealon does not displace any of those.
DIO2 Thr92Ala het. Impaired peripheral T4→T3 conversion. The Khavinson model claims pineal/circadian effects from Pinealon; if those effects were real, they could modulate the thyroid-circadian axis. Given the evidence base, this is a theoretical interaction rather than an actionable one.
CLOCK 3111T>C (rs1801260) CC. Sleep/circadian phase implications. Same caveat as DIO2 — the pineal/circadian claim would be relevant if real, but the underlying evidence does not support clinical recommendation.
MTHFR C677T het / methylation triple-burden. No direct interaction with Pinealon's proposed mechanism. If the free-amino-acid hypothesis is closer to the truth than the DNA-binding hypothesis, the free Asp and Glu would enter the same amino-acid pool that interacts with one-carbon metabolism, but the contribution from a microgram-dose peptide is trivial relative to dietary protein intake.
9p21.3 CAD risk genotypes. No specific interaction noted; the cardiovascular safety profile of Pinealon is not characterised.

Stack interactions

In Khavinson-school adherent protocols, Pinealon is typically stacked with Epitalon (the more famous cytogen, claimed pineal/telomerase effects — see §4.2 for methodological framing) and often with one or more additional cytogens (Vesugen, Cortagen) in rotating multi-week cycles. The mechanistic rationale offered is "complementary organ coverage" — Pinealon for cortex, Epitalon for pineal, Vesugen for vasculature, etc.

From a framework standpoint, the stack rationale rests on the same mechanism implausibility as the individual cytogens. Stacking multiple compounds with weak individual evidence does not strengthen the evidence base for any of them. The practical concern with multi-cytogen stacking is amplified exposure to grey-market supply-chain contamination risk — every additional peptide multiplies the endotoxin/impurity exposure surface.

Outside the Khavinson-school circuit, Pinealon is sometimes stacked with Selank or Semax (the other Russian short-peptide CNS programme — see §2.6, §2.7), reflecting the broader Russian neuropeptide research tradition. Selank and Semax have somewhat better mechanism plausibility (Selank is a heptapeptide analogue of tuftsin; Semax is a heptapeptide ACTH 4-10 fragment with established melanocortin/BDNF effects) and are placed in Tier 2 in this document, but the practical sourcing concerns are similar.

Framework alignment

Not strongly aligned, not strongly opposed. The if-it-works question on Pinealon — whether a peptide intervention could meaningfully attenuate age-related cognitive decline — is framework-compatible. Pillar 7 (cognitive and neurological reserve) and the broader anti-aging programme would welcome a real cognitive-protective compound if one existed.

The framework concerns are:

Mechanism implausibility as claimed. The site-directed DNA binding mechanism is not biophysically credible at the tripeptide scale, for the reasons in the critique section.
Evidence quality. No Western RCT, no independent replication of the strongest claims, no peer-reviewed biophysics of the proposed mechanism.
Supply-chain risk. Grey-market injectable peptide use carries endotoxin and contamination risk independent of the pharmacology of the active compound.
Opportunity cost. The interventions with stronger evidence for cognitive protection in framework terms (sleep prioritisation, B-vitamin methylation support, mercury/aluminium detoxification for those with relevant exposure, mitochondrial stack, seed-oil avoidance, regular cardiovascular and resistance exercise, low-dose lithium where indicated) are not displaced by adding Pinealon; they are diluted by it, both in attention and in budget.

Tier 4 placement holds primarily on evidence-quality and mechanism-plausibility grounds, not on direct framework opposition. A high-quality Western RCT showing genuine cognitive benefit in a well-defined population would warrant re-evaluation. That trial does not exist.

Evidence summary table

Claim	Evidence level	Notes
Pinealon binds DNA in sequence-specific manner	Weak; mechanism implausible	Information-theoretic ceiling on 3-mer specificity is ~13 bits; ~31.5 bits required to specify unique site in 3 Gb genome. No ITC/SPR/structural confirmation.
Pinealon penetrates the plasma membrane intact	Weak; biophysically implausible	Lacks cationic clusters, hydrophobic motifs, and helical propensity required of CPPs. Khavinson tracer studies not independently replicated by Western methods.
Pinealon survives serum peptidase exposure intact	Weak; pharmacokinetically implausible	Expected plasma half-life of unprotected linear tripeptide is minutes. No LC-MS/MS quantification of intact parent peptide in independent labs.
Pinealon improves cognition in aged rats	Moderate (animal, single-network)	Khavinson group and collaborators report consistent positive findings. Independent Western replication thin. Blinding and dose-response often inadequate.
Pinealon is neuroprotective in rodent hypoxia/ischemia	Moderate (animal, single-network)	Reduced apoptosis markers reported. Mechanism of action not verified with modern tools (ChIP-seq, RNA-seq).
Pinealon increases antioxidant enzyme activity in aged rat brain	Moderate (animal)	Reported downstream marker changes; upstream gene-regulation mechanism not tested.
Pinealon improves cognition in elderly humans	Weak	Small unblinded Russian trials only. No large Western RCTs. No Cochrane review. Not registered on ClinicalTrials.gov.
Pinealon reduces all-cause mortality in elderly humans	Very weak	Khavinson-network cohort studies only; unblinded; non-randomised in the modern sense. Healthy-user and selection bias not controlled.
Pinealon is FDA-approved or equivalent	False	Not approved in any Western pharmacopoeia. Sold as research chemical.
Pinealon is safe acutely in rodents	Strong	No acute toxicity at doses well above proposed therapeutic range.
Pinealon is safe long-term in healthy human adults	Untested	No long-term controlled human safety data.
Pinealon supply chain quality is reliable	Weak / negative	Russian vendor-dominated grey market; independent mass-spec verification absent; endotoxin risk unquantified.

Key references

Khavinson VK, Solovyov AY, Tarnovskaya SI, Linkova NS (2014) "Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression." Biochemistry (Moscow) Supplement Series B 8: 39-49 — foundational cytogen-mechanism paper from originating lab.
Khavinson VK, Malinin VV (2005) Gerontological Aspects of Genome Peptide Regulation. Karger, Basel — monograph statement of the peptide-bioregulation framework.
Khavinson VK (2011) "Peptide bioregulation: theory and practice." Neuro Endocrinol Lett 32 (Suppl 1): 1-6 — concise mechanistic claims summary.
Arutjunyan A, Kozina L, Stvolinskiy S et al. (2012) "Pinealon protects the rat offspring from prenatal hyperhomocysteinemia." Int J Clin Exp Med 5(2): 179-185 — prenatal hypoxia/hyperhomocysteinemia model from Khavinson-collaborating group.
Khavinson VK, Kuznik BI, Tarnovskaya SI, Lin'kova NS (2014) "Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data." Adv Gerontol 27(3): 399-406 — Russian-language oriented review.
Korkushko OV, Khavinson VK, Shatilo VB, Antonyuk-Shcheglova IA (2011) "Geroprotective effect of Epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging." Bull Exp Biol Med 151(3): 366-369 — Khavinson-network elderly cohort framework (Epitalon parent; relevant context for Pinealon claims).
Sikora E, Bielak-Zmijewska A, Mosieniak G (2016) "Cellular senescence in ageing, age-related disease and longevity" Curr Vasc Pharmacol 12(5): 698-706 — broader context for the gerosuppressive claims surrounding the Khavinson programme; written from outside the Khavinson network.
Crick FH (1968) "The origin of the genetic code." J Mol Biol 38: 367-379 — classical information-theory framing of sequence specificity that the cytogen DNA-binding model implicitly invokes.
Stormo GD (2000) "DNA binding sites: representation and discovery." Bioinformatics 16(1): 16-23 — modern treatment of the information content required to specify transcription factor binding sites in eukaryotic genomes; central to the information-theoretic objection.
Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A (2011) "Mechanisms of cellular uptake of cell-penetrating peptides." J Biophys 2011: 414729 — review of CPP structural requirements; underpins the cell-penetration objection.
Diao L, Meibohm B (2013) "Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides." Clin Pharmacokinet 52: 855-868 — review of peptide clearance and stability; underpins the serum peptidase objection.
Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) "Synthetic therapeutic peptides: science and market." Drug Discov Today 15: 40-56 — overview of why so few short linear peptides become drugs without stabilisation; relevant context.
Brown CM, Smith CA (2009) "The biophysics of transcription factor binding to DNA." Annu Rev Biophys 38: 41-58 — biophysics underpinning the affinity-verification objection.
Lindgren M, Hällbrink M, Prochiantz A, Langel Ü (2000) "Cell-penetrating peptides." Trends Pharmacol Sci 21: 99-103 — historical CPP review showing the cationic/amphipathic motif requirements.
Lau JL, Dunn MK (2018) "Therapeutic peptides: historical perspectives, current development trends, and future directions." Bioorg Med Chem 26: 2700-2707 — modern peptide therapeutics landscape; context for what Western pharma development of a real cognitive peptide would look like, by contrast with the cytogen programme.

Bottom line

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson's St Petersburg group as part of a "cytogen" programme that posits short peptides act as site-directed transcription factor mimetics regulating organ-specific gene expression. The central mechanistic claim is not biophysically credible at the tripeptide scale — a 3-mer carries ~13 bits of sequence information, well below the ~31.5 bits required to specify a unique site in a 3 Gb genome — and is not supported by the standard biophysics of peptide-DNA interaction, peptide cell penetration, or peptide pharmacokinetics. The rodent evidence base is suggestive of some biological effect in cognitive and ischemic models but is concentrated within the originating lab and lacks the independent Western replication, blinded methodology, and mechanism-of-action verification that would establish reliability. The human evidence base is small unblinded Russian trials; there is no Cochrane review, no FDA filing, and no large Western RCT. The supply chain is grey-market with endotoxin and identity verification risks. Tier 4 placement reflects the convergence of mechanism implausibility as claimed, evidence-quality failure, and supply-chain risk — not certainty that Pinealon is biologically inert. The legitimate scientific question (do short peptides do anything real for cognitive aging) deserves serious investigation; the current Twitter-promoted product is not a serious vehicle for that investigation. Higher-leverage cognitive-protection interventions for ε4 carriers and others concerned about cognitive aging include sleep prioritisation, B-vitamin methylation support, mercury and aluminium detoxification where indicated, mitochondrial support stack (CoQ10, taurine, magnesium, creatine), seed-oil avoidance, and regular cardiovascular and resistance exercise — none of which is displaced or improved by adding Pinealon.

4.4 Semaglutide / Tirzepatide / GLP-1 Receptor Agonists

Tier: 4 — Avoid (per existing framework position) Cross-reference: See SUPPLEMENTS.md Section 4.7 — GLP-1 Receptor Agonists / Semaglutide for the detailed framework critique.

Summary of framework position (not re-derived here): pharmacological appetite suppression via GLP-1 agonism produces rapid weight loss including substantial lean-mass loss; thyroid C-cell carcinoma signal in rodents (precaution rather than confirmed human risk); muscle-mass loss runs directly counter to framework Pillar 5 (anabolic capacity preservation); the underlying metabolic dysregulation that drives obesity is not addressed by appetite suppression and tends to re-emerge after discontinuation.

Detailed analysis: see SUPPLEMENTS.md §4.7.

End of document

Document metadata

First created: 2026-05-24
Scope: therapeutic peptides through the bioenergetic longevity framework lens
Sibling document: SUPPLEMENTS.md
Status: BPC-157 (§2.1) and Pinealon (§4.3) deep dives complete; Khavinson methodological overview (§4.2) expanded; all other entries are stubs pending future expansion
Framework consistency principle applied: GH/GHRH/GHRP/GHS class placed in Tier 3 not Tier 2 on grounds of chronic IGF-1 → mTOR concern, despite mainstream longevity culture's enthusiasm; mitochondrial peptides (MOTS-c, SS-31, Humanin) and thymosin α-1 placed in Tier 1 as direct framework matches; Khavinson school placed in Tier 4 on evidence-quality grounds with information-theoretic critique of the 3-mer site-directed DNA binding mechanism articulated in the Pinealon deep dive; BPC-157 placed in Tier 2 not Tier 1 because of human RCT evidence gap and VEGF/cancer concern.

101 KiB Raw Blame History Unescape Escape

PEPTIDES.md — Therapeutic Peptides Through the Bioenergetic Longevity Lens

Table of Contents

Framework Introduction

The bioenergetic framework applied to peptide pharmacology

Why peptides as a class — and why caution

Routes of administration and bioavailability primer

The "research chemical" sourcing problem

Cancer concerns for growth-promoting peptides

Tier 1 — Strongly Aligned

1.1 MOTS-c

1.2 SS-31 (Elamipretide)

1.3 Humanin

1.4 Thymosin α-1

Tier 2 — Aligned, Context-Dependent

2.1 BPC-157 (Body Protection Compound)

Discovery and structure

Pharmacology — the oral vs subcutaneous controversy

Proposed mechanisms

Rodent evidence base — the Sikiric corpus

Human evidence — the critical gap

The cancer concern

Safety profile

Dosing protocols (commonly used; not endorsed)

Genotype interactions

Stack interactions

Sourcing concerns

Framework alignment

Evidence summary table

Key references

Bottom line

2.2 TB-500 / Thymosin β-4

2.3 GHK-Cu

2.4 Pentadeca-Arginate (PDA)

2.5 LL-37 / Cathelicidin

2.6 Selank

2.7 Semax

2.8 DSIP (Delta Sleep-Inducing Peptide)

2.9 Thymalin

Tier 3 — Mixed / Complicated

3.1 Tesamorelin

3.2 Sermorelin

3.3 CJC-1295 (with and without DAC)

3.4 Ipamorelin

3.5 Hexarelin

3.6 MK-677 / Ibutamoren

3.7 Cerebrolysin

3.8 PT-141 / Bremelanotide

3.9 Kisspeptin-10

3.10 Melanotan I (Afamelanotide / Scenesse)

Tier 4 — Avoid

4.1 Melanotan II

4.2 Khavinson School Bioregulators — Methodological Overview (Epitalon, Vesugen, and the wider "peptide bioregulator" pharmacopoeia)

4.3 Pinealon (Glu-Asp-Arg / EDR)

Discovery and structure

Proposed mechanisms — the Khavinson model

Mechanism critique — the skeptical reading

Animal evidence

Human evidence — the critical gap

Bioavailability problem

Social media framing concern

Sourcing concerns

Safety profile

Genotype interactions

Stack interactions

Framework alignment

Evidence summary table

Key references

Bottom line

4.4 Semaglutide / Tirzepatide / GLP-1 Receptor Agonists

End of document

Document metadata

101 KiB

Raw Blame History